AZD2066 Cocktail Study

• Status: Completed
• Trial end date: 2009-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The aims of this study are to examine the effect of repeated doses of AZD2066 and of caffeine, bupropion, tolbutamide, omeprazole, metoprolol and midazolam on the blood concentrations of each other

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: AstraZeneca
• Treatments: Bupropion; Caffeine; Metoprolol; Midazolam; Omeprazole; Tolbutamide

Criteria

Inclusion Criteria:

• Provision of informed consent prior to any study-specific procedures

• Healthy volunteers with BMI between 18 and 30 kg/m2

• Medical and surgical history and physical examination without any clinically significant findings

• Non smokers or past smokers who have stopped smoking within the last 6 months.

Exclusion Criteria:

• History of previous or ongoing psychiatric disease/condition including psychosis, affective disorder, anxiety disorder, personality disorder or other significant psychiatric disorders or any other major disorder that may interfere with the objectives of the study, as judged by the Investigator

• Clinically significant illness as judged by the Investigator, within four weeks before the first administration of investigational product.

• Female subjects who have a positive pregnancy test or who are pregnant or breast-feeding